BioStock: Cyxone has closed recruitment to the phase II Covid-19 trial

Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to a close as a sufficient number of patients have been enrolled to power an effective analysis. BioStock reached out to Cyxone’s CEO Tara Heitner to get her thoughts on the implications of the news.

Read the full interview with CEO Tara Heitner at biostock.se:

https://www.biostock.se/en/cyxone-has-closed-recruitment-to-the-phase-ii-covid-19-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/